Clinical Trial

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-17
Trial Details
NCT Number NCT07404553
Lead Sponsor Beijing Suncadia Pharmaceuticals Co., Ltd
Conditions Hypercholesterolemia
Enrollment 126 participants
Start Date 2026-04-30
Primary Completion 2028-07 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-16